Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. - Wikidata - wikimedia - TriplyDB

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

http://www.wikidata.org/entity/Q34936117

about

The value of trabectedin in the treatment of soft tissue sarcoma Trabectedin for advanced soft tissue sarcomas: optimizing use Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas Recent advances in targeted therapy for Ewing sarcoma Trabectedin in soft tissue sarcomas Regulation of Cellular Identity in Cancer Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma Trabectedin for the management of soft-tissue sarcoma.Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications.Role of trabectedin in the treatment of soft tissue sarcoma New therapeutic targets in soft tissue sarcoma.Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts).PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma Advances in the targeted therapy of liposarcoma.Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.Normal and functional TP53 in genetically stable myxoid/round cell liposarcoma.Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Advances in sarcoma genomics and new therapeutic targets.Solid tumor differentiation therapy - is it possible?Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma.Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to know Hyperexpression of HOXC13, located in the 12q13 chromosomal region, in well‑differentiated and dedifferentiated human liposarcomas.Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Liposarcoma: molecular genetics and therapeutics.Spermatic cord myxoid liposarcoma presenting as an incarcerated inguinal hernia: report of a case and review of literatures.Systemic management strategies for metastatic soft tissue sarcoma.Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery.Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.

P2860

Q26772855-9955E5C9-A13A-4504-9618-5FBF043556D5 Q26860365-34C47360-15EB-4D0A-AC7D-23211AA7790B Q28076210-66D57CD8-81A5-4F1D-BF2C-813F317F1C34 Q28079316-A045BE82-93A3-47F8-B2C4-8FF7BE046EB0 Q28085505-F024139E-8E84-4FAD-A4E3-6E856482D7CF Q28086849-BA1E2BD7-D01B-4705-BC5C-758BFA68BE5B Q28307320-BF5936A3-B286-4618-BBE3-7C0F72059462 Q28482357-D8DB4F6A-C610-44BE-B598-35C11198D252 Q33384836-14AA2CB9-4CA2-4932-A41F-7298DCB90549 Q33426789-3798E808-DF14-4BCC-A99D-3B8695B13128 Q33649056-DEE9BE07-C565-47EE-B875-599254ED1A02 Q33757142-369F0148-D3B9-4FD0-B821-5440857EC72E Q33916011-8264960B-5DA7-4307-912D-3F72085D175B Q34267924-7331642F-3353-412D-9FFE-BF9F57AE2F9F Q34356540-4426381F-1C47-44B5-9CBB-4F07A8ECB383 Q34609393-97CBF587-83EF-45C8-8746-60560690398B Q34635550-349318A6-E019-43DA-854D-E6E814ABBCCF Q34952133-EEF90C37-582E-4305-8179-78356A8DB9B9 Q35058617-B730BAE3-9294-4C6F-A41F-EDD31EEADAD0 Q35416886-3BBB77D4-41AA-4A5F-83FD-C8B6D3B5C20D Q35898258-FEB77C13-60F4-4D64-B5A1-87E698266163 Q35993346-0FF57051-6A48-4DF5-9135-849A8581EC67 Q36071880-C697E17A-577E-46AE-B420-F972D24B9FEA Q36073121-B7303AD8-F3CD-4EA4-A2B4-C22D6BFD58A8 Q36078294-5E000842-B18A-4F89-87BE-6088196F7D1F Q36326279-9355DF40-94C6-442B-B588-4C38E4DFDB64 Q36389964-FA3160C4-E7FF-4F29-B39F-7E19CDB821E7 Q36432104-AF7A8971-2F30-47F1-A176-AA16ADD41392 Q36819466-87C0B5F7-C10B-497F-9355-4B8139E1A988 Q37341266-CB3E5C67-E777-4EC7-B617-17BB8A4C9D87 Q37350801-23A00EB8-8F7E-4529-80AD-81ACFEFD1EF8 Q37669484-E57CC142-20F1-4CB6-914F-D7AD00F47249 Q37760957-49B60526-A360-46FB-94F8-DB9306E311EF Q37831160-6DA71896-73C8-4F89-96BF-A83534A4BBFB Q37851053-36EE0CBD-E4CD-4499-83D1-19426B574BED Q37950516-53800B06-CB31-4140-946B-EDC388B01995 Q37969213-44587FBC-24BF-4296-A009-20CD7D937E79 Q38000323-D44EA191-73CA-4738-9C0C-B0F5512EE32F Q38161734-444CFA09-4EA0-4E65-A9E7-5613A0E4328B Q38197031-5F69D363-B94B-463F-8CDD-F902A31F76B2

P2860

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

http://www.wikidata.org/entity/Q34936117

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

@ast

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

@en

Trabectedin

@nl

type

label

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

@ast

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

@en

Trabectedin

@nl

prefLabel

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

@ast

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

@en

Trabectedin

@nl

P1433

Q34936117-9851CFA1-02DA-4575-988A-45D6E3A9CA88

P1476

Q34936117-418CE092-EACF-40D2-BF76-8A1EC35A7B95

P2093

Q34936117-10D7C0C7-DC58-4CFC-9AC0-8CAEDB206EBF

Q34936117-2F77713D-3171-44CE-9F3E-ECD294955947

Q34936117-3EE7FD24-B212-47FC-A139-6240ED65B8D7

Q34936117-3F266123-4731-4029-9CE5-B40D29269C4C

Q34936117-50E3A1DE-2AA4-456C-932A-5D3E45069FD2

Q34936117-6439505F-651A-4DF7-B0D1-326E193D6F15

Q34936117-A0A253F5-3CA3-4DFC-A274-7E08C88A53D5

Q34936117-AC647C5E-1DFD-4C67-96BB-17B156F3C6A2

Q34936117-E776B6F9-73C8-4356-A71E-CF4B58046436

Q34936117-EC7F6E45-E8EB-455E-B97A-2B834F9BC7FD

P304

Q34936117-517B2748-B1B0-4E2D-A082-96BDBB14ADF7

P31

Q34936117-0252FBE8-476E-4EA4-8D0D-BA2F325F0E20

P356

Q34936117-C4CA0AD6-0086-4D1E-9FCA-F0ACFBD5730A

P433

Q34936117-820C0F56-7316-4F40-85DB-23C9397B7383

P478

Q34936117-8BD6F33E-86AB-4051-AC86-DB02DA0F675F

P50

Q34936117-3831A7A4-4D92-4ADD-9B9A-AEC3C60777D0

Q34936117-4BE84496-28AB-4126-9C9F-DDEDC7B13592

Q34936117-5CF0610B-6A08-4893-8AFA-1EA5C9DA727E

Q34936117-6F476A48-713B-4ED5-A190-8B9ECE1FB438

P577

Q34936117-757E24B4-29E3-47FA-8F50-EA441D9F21B2

P5875

Q34936117-D55CFFCC-8EF1-455D-9059-BA7146DA12BC

P698

Q34936117-6452738E-7C23-44EE-9653-C674AE2B76BF

P356

1535-7163.MCT-08-0848

P1433

Molecular Cancer Therapeutics

P1476

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

@en

P2093

Claudia Forni

http://www.w3.org/2001/XMLSchema#string

Emanuela Virdis

http://www.w3.org/2001/XMLSchema#string

Eugenio Erba

http://www.w3.org/2001/XMLSchema#string

Federica Grosso

http://www.w3.org/2001/XMLSchema#string

Mario Minuzzo

http://www.w3.org/2001/XMLSchema#string

Matteo Simone

http://www.w3.org/2001/XMLSchema#string

Michele Tavecchio

http://www.w3.org/2001/XMLSchema#string

Pierre Aman

http://www.w3.org/2001/XMLSchema#string

Roberto Mantovani

http://www.w3.org/2001/XMLSchema#string

Silvana Pilotti

http://www.w3.org/2001/XMLSchema#string

P304

449-457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-08-0848

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Alessandro Gronchi

Paolo Giovanni Casali

Elena Tamborini

Maurizio D'Incalci

P577

2009-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23974390

http://www.w3.org/2001/XMLSchema#string

P698

19190116

http://www.w3.org/2001/XMLSchema#string